华东医药：由中美华东申报的注射用HDM2017临床试验申请获得批准

Group 1 - The core point of the article is that Huadong Medicine's subsidiary has received approval for a clinical trial of an injectable drug, HDM2017, from the National Medical Products Administration (NMPA) [1] - As of the first half of 2025, Huadong Medicine's revenue composition is as follows: 68.23% from commercial brokerage and agency, 33.94% from pharmaceutical manufacturing, 4.57% from medical aesthetics, and 0.77% from other businesses, with inter-segment eliminations accounting for -7.5% [1] - The current market capitalization of Huadong Medicine is 73.2 billion yuan [1]